Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis

References

• Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68. doi:10.1164/rccm.201807-1255ST30168753
   PubMed Web of Science ®Google Scholar
• Raghu G, Chen S-Y, Yeh W-S, et al. Idiopathic pulmonary fibrosis in US medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2(7):566–572. doi:10.1016/S2213-2600(14)70101-824875841
   PubMed Web of Science ®Google Scholar
• Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–440. doi:10.1164/rccm.201006-0894CI20935110
   PubMed Web of Science ®Google Scholar
• Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194(3):265–275. doi:10.1164/rccm.201604-0801CI27299520
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet Lond Engl. 2011;377(9779):1760–1769. doi:10.1016/S0140-6736(11)60405-4
   PubMed Web of Science ®Google Scholar
• King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092. doi:10.1056/NEJMoa140258224836312
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082. doi:10.1056/NEJMoa140258424836310
   PubMed Web of Science ®Google Scholar
• Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci off J Eur Fed Pharm Sci. 2014;58:13–19. doi:10.1016/j.ejps.2014.02.014
   PubMed Web of Science ®Google Scholar
• Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008;590(1–3):400–408. doi:10.1016/j.ejphar.2008.06.04618598692
   PubMed Web of Science ®Google Scholar
• Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5(1):33–41. doi:10.1016/S2213-2600(16)30326-527876247
   PubMed Web of Science ®Google Scholar
• Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171(9):1040–1047. doi:10.1164/rccm.200404-571OC15665326
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):821–829. doi:10.1183/09031936.0000520919996196
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47(1):243–253. doi:10.1183/13993003.00026-201526647432
   PubMed Web of Science ®Google Scholar
• Nathan SD, Albera C, Bradford WZ, et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax. 2016;71(5):429–435. doi:10.1136/thoraxjnl-2015-20701126968970
   PubMed Web of Science ®Google Scholar
• Costabel U, Albera C, Lancaster LH, et al. An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP). Respir Int Rev Thorac Dis. 2017;94(5):408–415. doi:10.1159/000479976
   Web of Science ®Google Scholar
• Costabel U, Albera C, Glassberg MK, et al. Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. Respir Res. 2019;20(1):55. doi:10.1186/s12931-019-1021-230866942
   PubMed Web of Science ®Google Scholar
• Zurkova M, Kriegova E, Kolek V, et al. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry. Respir Res. 2019;20(1):16. doi:10.1186/s12931-019-0977-230665416
   PubMed Web of Science ®Google Scholar
• Agarwal R, Jindal SK. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur J Intern Med. 2008;19(4):227–235. doi:10.1016/j.ejim.2007.04.02418471669
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671. doi:10.1164/rccm.201104-0597OC21680942
   PubMed Web of Science ®Google Scholar
• Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med. 2014;190(7):773–779. doi:10.1164/rccm.201403-0566OC25162152
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824. doi:10.1164/rccm.2009-040GL21471066
   PubMed Web of Science ®Google Scholar
• Gaudry S, Vincent F, Rabbat A, et al. Invasive mechanical ventilation in patients with fibrosing interstitial pneumonia. J Thorac Cardiovasc Surg. 2014;147(1):47–53. doi:10.1016/j.jtcvs.2013.06.03923968871
   PubMed Web of Science ®Google Scholar
• Vianello A, Arcaro G, Battistella L, et al. Noninvasive ventilation in the event of acute respiratory failure in patients with idiopathic pulmonary fibrosis. J Crit Care. 2014;29(4):562–567. doi:10.1016/j.jcrc.2014.03.01924768565
   PubMed Web of Science ®Google Scholar
• Ley B, Swigris J, Day B, et al. Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2017;196(6):756–761. doi:10.1164/rccm.201701-0091OC28471697
   PubMed Web of Science ®Google Scholar
• Furuya K, Sakamoto S, Shimizu H, et al. Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study. Respir Med. 2017;126:93–99. doi:10.1016/j.rmed.2017.03.02628427556
   PubMed Web of Science ®Google Scholar
• Kataoka K, Taniguchi H, Kondoh Y, et al. Recombinant human thrombomodulin in acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2015;148(2):436–443. doi:10.1378/chest.14-274625811735
   PubMed Web of Science ®Google Scholar
• van Manen MJG, Birring SS, Vancheri C, et al. Cough in idiopathic pulmonary fibrosis. Eur Respir Rev off J Eur Respir Soc. 2016;25(141):278–286. doi:10.1183/16000617.0090-2015
   PubMed Web of Science ®Google Scholar
• van Manen MJG, Birring SS, Vancheri C, et al. Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2017;50:4. doi:10.1183/13993003.01157-2017
   Web of Science ®Google Scholar
• Glassberg MK, Wijsenbeek MS, Gilberg F, Petzinger U, Kirchgaessler K-U, Albera C. Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019;54:1900399. doi:10.1183/13993003.00399-201931164431
   PubMed Web of Science ®Google Scholar
• Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther. 2009;22(4):279–285. doi:10.1016/j.pupt.2009.03.00319328861
   PubMed Web of Science ®Google Scholar
• Nathan SD, Lancaster LH, Albera C, et al. Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials. BMJ Open Respir Res. 2018;5(1):e000323. doi:10.1136/bmjresp-2018-000323
   PubMed Web of Science ®Google Scholar
• Cottin V, Koschel D, Günther A, et al. Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study. ERJ Open Res. 2018;4:4. doi:10.1183/23120541.00084-2018
   Google Scholar
• Uehara M, Enomoto N, Karayama M, et al. Evaluation of pirfenidone dose adjusted by body weight or body surface area in the treatment for Japanese patients with interstitial pneumonia. In: C38. UNDERSTANDING THERAPEUTICS IN IPF. American Thoracic Society International Conference Abstracts American Thoracic Society; 2017:6A5401–A5401. doi:10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A5401
   Google Scholar
• Sakayori M, Terada J, Abe M, et al. Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis. Drug Des Devel Ther. 2019;13:2295–2303. doi:10.2147/DDDT.S208733
   PubMed Web of Science ®Google Scholar
• Side effects and safety data | esbriet® (pirfenidone) HCP. Available from: https://www.esbriethcp.com/safety-tolerability-dosing/safety-tolerability.html. Accessed 72, 2019.
   Google Scholar
• Lederer DJ, Martinez FJ, Longo DL. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378(19):1811–1823. doi:10.1056/NEJMra170575129742380
   PubMed Web of Science ®Google Scholar
• Khanna D, Albera C, Fischer A, et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol. 2016;43(9):1672–1679. doi:10.3899/jrheum.15132227370878
   PubMed Web of Science ®Google Scholar
• Chaudhary NI, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007;29(5):976–985. doi:10.1183/09031936.0015210617301095
   PubMed Web of Science ®Google Scholar
• Noth I, Oelberg D, Kaul M, Conoscenti CS, Raghu G. Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA. Eur Respir J. 2018;52:1. doi:10.1183/13993003.02106-2017
   Web of Science ®Google Scholar
• Noth I, Wijsenbeek M, Kolb M, et al. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials. Eur Respir J. 2019;54:3. doi:10.1183/13993003.01797-2018
   Web of Science ®Google Scholar
• Barratt SL, Mulholland S, Al Jbour K, et al. South-West of England’s experience of the safety and tolerability pirfenidone and nintedanib for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Front Pharmacol. 2018;9:1480. doi:10.3389/fphar.2018.0148030618768
   PubMed Web of Science ®Google Scholar
• Okuda R, Hagiwara E, Baba T, Kitamura H, Kato T, Ogura T. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med. 2013;107(9):1431–1437. doi:10.1016/j.rmed.2013.06.01123849626
   PubMed Web of Science ®Google Scholar
• Wijsenbeek MS, Van Beek FT, Geel AL, et al. Pirfenidone in daily clinical use in patients with idiopathic pulmonary fibrosis in the Netherlands. In: C48. INTERSTITIAL LUNG DISEASE: OUTCOMES, TREATMENT, AND EXACERBATION. American Thoracic Society International Conference Abstracts American Thoracic Society; 2013:A4340. doi:10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A4340
   Google Scholar
• Ravaglia C, Gurioli C, Romagnoli M, et al. Pirfenidone treatment in idiopathic pulmonary fibrosis: an Italian case series. Eur Respir J. 2013;42(Suppl 57):P3370.
   Google Scholar
• Bonella F, Wessendorf TE, Costabel U. Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis. Dtsch Med Wochenschr. 2013;138(11):518–523. doi:10.1055/s-0032-133293023423955
   PubMed Web of Science ®Google Scholar
• Arai T, Inoue Y, Sasaki Y, et al. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir Investig. 2014;52(2):136–143. doi:10.1016/j.resinv.2013.09.002
   PubMedGoogle Scholar
• Oltmanns U, Kahn N, Palmowski K, et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respir Int Rev Thorac Dis. 2014;88(3):199–207. doi:10.1159/000363064
   Web of Science ®Google Scholar
• Chaudhuri N, Duck A, Frank R, Holme J, Leonard C. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir Med. 2014;108(1):224–226. doi:10.1016/j.rmed.2013.11.00524269005
   PubMed Web of Science ®Google Scholar
• Hanta I, Cilli A, Sevinc C. The effectiveness, safety, and tolerability of pirfenidone in idiopathic pulmonary fibrosis: a retrospective study. Adv Ther. 2019;36(5):1126–1131. doi:10.1007/s12325-019-00928-330900199
   PubMed Web of Science ®Google Scholar
• Yoon H-Y, Kim DS, Song JW. Efficacy and safety of pirfenidone in advanced idiopathic pulmonary fibrosis. Respir Int Rev Thorac Dis. 2019;97(3):242–251. doi:10.1159/000492937
   Web of Science ®Google Scholar
• Tzouvelekis A, Ntolios P, Karampitsakos T, et al. Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis: a real-world observational study. Pulm Pharmacol Ther. 2017;46:48–53. doi:10.1016/j.pupt.2017.08.01128843616
   PubMed Web of Science ®Google Scholar
• Margaritopoulos GA, Trachalaki A, Wells AU, et al. Pirfenidone improves survival in IPF: results from a real-life study. BMC Pulm Med. 2018;18(1):177. doi:10.1186/s12890-018-0736-z30470213
   PubMed Web of Science ®Google Scholar
• Salih GN, Shaker SB, Madsen HD, Bendstrup E. Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results. Eur Clin Respir J. 2016;3:32608. doi:10.3402/ecrj.v3.3260827616539
   PubMed Web of Science ®Google Scholar
• Esbriet® (pirfenidone) information for healthcare professionals. Available from: https://www.esbriethcp.com/index.html?c=esb-1631d3792bb&gclid=Cj0KCQiAgebwBRDnARIsAE3eZjT6zHuuSFTLEn1qp7upWzTKgjKDQbbrrOH5Fs0oOdnV8vnQisd4J3YaAqsjEALw_wcB&gclsrc=aw.ds. Accessed 111, 2020.
   Google Scholar